Extracorporeal hemoadsorption in critically ill COVID-19 patients on VV ECMO: the CytoSorb therapy in COVID-19 (CTC) registry
Authors' conclusion
In critically ill patients with severe COVID-19-related ARDS treated with the combination of VV-ECMO and hemoadsorption, 90-day survival was 74% and earlier intervention was associated with shorter need for organ support and ICU stay.
Study context
- Population
- Critically ill adults with COVID-19-related acute respiratory distress syndrome (ARDS) requiring VV ECMO, treated with extracorporeal hemoadsorption, intensive care units (ICUs) of five US academic centres, April 2020–January 202263% male
- Participants
- 100 adults
- Exposure
- Early vs late start of hemoadsorption from ICU admission
- Outcome
- Mortality (time-to-event analysis)
Methodological detailsmulticentre, post hoc groups
- Multicentre
- Post hoc groups
Main finding
As reported in the abstract
Survival
Survival at 30 days
86%
Survival at 90 days
74%
Observational data: associations, not effects.
Further findings
Duration of mechanical ventilation after start of hemoadsorption · post hoc groups
P = 0.02
Duration of ECMO support after start of hemoadsorption · post hoc groups
P = 0.021
ICU stay after start of hemoadsorption · post hoc groups
P = 0.002
Survival · 90 days · post hoc groups
P = 0.14
Safety
- No device-related adverse events reported
Original publication
Extracorporeal hemoadsorption in critically ill COVID-19 patients on VV ECMO: the CytoSorb therapy in COVID-19 (CTC) registry. Crit Care. Published 19 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →